Tsu E C
Am J Hosp Pharm. 1978 Dec;35(12):1507-15.
The thrombotic process, basic mechanisms of action of antiplatelet drugs, and clinical trials with platelet inhibitors are reviewed. The role of prostaglandins in platelet reactions and the mechanisms of aspirin's, dipyridamole's and sulfinpyrazone's inhibition of platelet function are discussed. Clinical studies of the use of these three drugs, alone or in combination with each other or with anticoagulants, for the treatment of thrombotic disorders associated with valvular heart disease, prosthetic heart valves, cerebral vascular disease (e.g., transient ischemic attacks), coronary artery diseases (including myocardial infarction), peripheral vascular disease, renal disease and renal allograft rejection are reviewed and evaluated. Clinical evidence suggests that antiplatelet drugs are useful in preventing thromboembolism associated with coronary and cerebral vascular disorders. In peripheral vascular and renal diseases and in renal allografts, their benefits have not been proved. Further controlled clinical studies of the preventive use of these drugs for arterial thrombosis are needed.
本文综述了血栓形成过程、抗血小板药物的基本作用机制以及血小板抑制剂的临床试验。讨论了前列腺素在血小板反应中的作用以及阿司匹林、双嘧达莫和磺吡酮抑制血小板功能的机制。对这三种药物单独使用、相互联合或与抗凝剂联合用于治疗与瓣膜性心脏病、人工心脏瓣膜、脑血管疾病（如短暂性脑缺血发作）、冠状动脉疾病（包括心肌梗死）、外周血管疾病、肾脏疾病和肾移植排斥反应相关的血栓性疾病的临床研究进行了综述和评估。临床证据表明，抗血小板药物在预防与冠状动脉和脑血管疾病相关的血栓栓塞方面是有用的。在外周血管疾病和肾脏疾病以及肾移植中，其益处尚未得到证实。需要进一步进行对照临床研究，以探讨这些药物预防性用于动脉血栓形成的情况。
